Nebenwirkungen · Yescarta
Yescarta 0.4 – 2 × 108 cells dispersion for infusion · Abschnitt 4.8 · PDF-Seite 15
HOS-139714 · Präparat HOS-098384
Hypogammaglobulinaemia Hypogammaglobulinaemia was reported in 15% of patients treated with Yescarta. Cumulatively, 36 (33%) of 108 patients in ZUMA-1 received intravenous immunoglobulin therapy by the time of the 54-month analysis, 28 (16%) of 170 patients in ZUMA-7 received intravenous immunoglobulin therapy by the time of the 23.2 month analysis and 33 (28%) of 119 subjects in ZUMA-5 received intravenous immunoglobulin therapy at the time of the 24-month follow-up analysis. In ZUMA-7, immunoglobulins decreased was reported in 11% of patients treated with Yescarta compared to 1% of patients treated with SOCT. See section 4.4 for management guidance.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-08T14:29:00Z · SHA-256 7364b8713752a41eb6e8333150b68c1c6ab4a679e9b42caeedeacec6f055396e · Passage 73631e5a06296a409f0695b25e2494b35ec831727995b526e9325368cc22f856 · Zeichen 22208–22866 im Abschnitt